February 22, 2018 06:43 AM ESTUpdated 08:13 AM
R&D

In a turf war with Eli Lil­ly, No­vo Nordisk steps off with pos­i­tive PhI­II for its chal­leng­ing oral GLP-1 drug

John Carroll

Editor & Founder

Just a cou­ple of months af­ter No­vo Nordisk shook up the big di­a­betes mar­ket with the ar­rival of its GLP-1 drug Ozem­pic (semaglu­tide) in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times